The estimated Net Worth of Mel Sorensen is at least $2.49 Milion dollars as of 16 August 2024. J Sorensen owns over 67,015 units of Galera Therapeutics Inc stock worth over $19,347 and over the last 5 years he sold GRTX stock worth over $4,691. In addition, he makes $2,465,100 as President, Chief Executive Officer a Director at Galera Therapeutics Inc.
Sign up
J Sorensen GRTX stock SEC Form 4 insiders trading
J has made over 3 trades of the Galera Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 67,015 units of GRTX stock worth $4,691 on 16 August 2024.
The largest trade he's ever made was exercising 217,015 units of Galera Therapeutics Inc stock on 26 March 2021 worth over $236,546. On average, J trades about 54,861 units every 177 days since 2020. As of 16 August 2024 he still owns at least 265,029 units of Galera Therapeutics Inc stock.
You can see the complete history of J Sorensen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
J. Mel Sorensen biography
Dr. J. Mel Sorensen M.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Sorensen serves on the boards of several private biopharmaceutical companies, as director or Chairman, including Oncopia Therapeutics, OncoFusion Therapeutics, Esanik Therapeutics and Context Therapeutics. He is an advisor to the Biomarkers Consortium of the National Institutes of Health and to the Irish Cancer Society. Dr. Sorensen holds an M.B., B.Ch. and B.A.O. from University College, Dublin. Dr. Sorensen’s postgraduate education and work has been in the United States, including an internal medicine residency in St. Louis and medical oncology fellowship at the Mayo Clinic, seven years at the National Cancer Institute as Senior Investigator in the Cancer Therapy Evaluation Program and four years each with Bayer and GlaxoSmithKline. Dr. Sorensen served as Director, Chief Executive Officer and President of Ascenta Therapeutics from 2004 until he joined Galera. Sorensen is qualified to serve on our Board of Directors due to his experience in the biopharmaceutical industry, his role as our Chief Executive Officer and President, and his knowledge of the Company.
What is the salary of J Sorensen?
As the President, Chief Executive Officer a Director of Galera Therapeutics Inc, the total compensation of J Sorensen at Galera Therapeutics Inc is $2,465,100. There are no executives at Galera Therapeutics Inc getting paid more.
How old is J Sorensen?
J Sorensen is 63, he's been the President, Chief Executive Officer a Director of Galera Therapeutics Inc since 2012. There are 6 older and 9 younger executives at Galera Therapeutics Inc. The oldest executive at Galera Therapeutics Inc is Joel F. Sussman, 72, who is the Chief Accounting Officer & Treasurer.
What's J Sorensen's mailing address?
Mel's mailing address filed with the SEC is C/O GALERA THERAPEUTICS, INC.,, 45 LIBERTY BLVD #230, MALVERN, PA, 19355.
Insiders trading at Galera Therapeutics Inc
Over the last 5 years, insiders at Galera Therapeutics Inc have traded over $19,201,067 worth of Galera Therapeutics Inc stock and bought 3,540,438 units worth $29,883,202 . The most active insiders traders include Holdings A/S Novo, Group Inc Blackstone Group ... a Bioventures Ltd Novartis Ag.... On average, Galera Therapeutics Inc executives and independent directors trade stock every 47 days with the average trade being worth of $11,809. The most recent stock trade was executed by Mel Sorensen on 16 August 2024, trading 67,015 units of GRTX stock currently worth $4,691.
What does Galera Therapeutics Inc do?
galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.
What does Galera Therapeutics Inc's logo look like?
Complete history of J Sorensen stock trades at Galera Therapeutics Inc
Galera Therapeutics Inc executives and stock owners
Galera Therapeutics Inc executives and other stock owners filed with the SEC include:
-
J. Mel Sorensen,
President, Chief Executive Officer, Director -
Christopher Degnan,
Chief Financial Officer -
Robert Beardsley,
Chief Operating Officer -
Dr. J. Mel Sorensen,
CEO, Pres & Director -
Christopher Degnan,
CFO & Sec. -
Dr. Robert A. Beardsley,
Co-Founder & COO -
Arthur Fratamico,
Chief Business Officer -
Jon Holmlund,
Chief Medical Officer -
Lawrence Alleva,
Independent Director -
Michael Powell,
Independent Chairman of the Board -
Emmett Cunningham,
Director -
Kevin Lokay,
Independent Director -
Linda West,
Independent Director -
Joel Sussman,
Chief Accounting Officer -
Mark J. Bachleda M.B.A., Pharm.D.,
Chief Commercial Officer -
Arthur J. Fratamico,
Chief Bus. Officer -
Dr. Jon T. Holmlund,
Chief Medical Officer -
Jennifer Evans Stacey Esq.,
Chief Legal & Compliance Officer and Sec. -
Dr. Dennis P. Riley Ph.D.,
Chief Scientific Officer -
Joel F. Sussman,
Chief Accounting Officer & Treasurer -
Bioventures Ltd Novartis Ag...,
-
Chris Degnan,
Chief Financial Officer -
Jason Fuller,
Director -
Iv A, L.P.Clarus Iv B, L.P....,
-
Group Inc Blackstone Group ...,
-
Clarus Gp L.P.Blackstone Cl...,
-
Enterprise Associates 14, L...,
-
Venture Partners Ix, L.P.So...,
-
Dennis Riley,
Chief Scientific Officer -
Holdings A/S Novo,
10% owner -
Mark Bachleda,
Chief Commercial Officer -
Jennifer Evans Stacey,
See Remarks -
Yair Schneid,
10% owner -
Eugene P. Kennedy,
Chief Medical Officer -
Mel Sorensen,
President and CEO